Retraction Note to: SDF-1/CXCR4 Axis Regulates Cell Cycle Progression and Epithelial-Mesenchymal Transition via Up-regulation of Survivin in Glioblastoma (Molecular Neurobiology, (2016), 53, 1, (210-215), 10.1007/s12035-014-9006-0);SDF-1/CXCR4 Axis Regulates Cell Cycle Progression and Epithelial-Mesenchymal Transition via Up-regulation of Survivin in Glioblastoma

Molecular Neurobiology

Volumn 53, Issue 1, 2016, Pages 210-215

  Liao, Anyan ^a   Shi, Ranran ^b   Jiang, Yuliang ^a   Tian, Suqing ^a   Li, Panpan ^c   Song, Fuxi ^c   Qu, Yalan ^c   Li, Jinna ^a   Yun, Haiqin ^d   Yang, Xiangshan ^e  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d SHANDONG UNIVERSITY   (China)

^e SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle progression; EMT; SDF 1 CXCR4; Survivin

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; MITOGEN ACTIVATED PROTEIN KINASE; NERVE CELL ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1; SURVIVIN; TRANSCRIPTION FACTOR SNAIL; BIRC5 PROTEIN, HUMAN; CXCL12 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN;

ARTICLE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GENETIC TRANSFECTION; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; U 251 CELL LINE; UPREGULATION; WESTERN BLOTTING; CELL CYCLE; CELL SURVIVAL; GLIOBLASTOMA; METABOLISM; PHYSIOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOKINE CXCL12; EPITHELIAL-MESENCHYMAL TRANSITION; GLIOBLASTOMA; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CXCR4; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84953365694     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-017-0508-4     Document Type: Erratum

References (27)

1. Buckner JC (2003) Factors influencing survival in high-grade gliomas. Semin Oncol 30(6 Suppl 19):10–14
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
3. Woodworth GF, Dunn GP, Nance EA, Hanes J, Brem H (2014) Emerging insights into barriers to effective brain tumor therapeutics. Front Oncol 4:126
4. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49(3):333–343
5. Moustakas A, Heldin P (2014) TGFβ and matrix-regulated epithelial to mesenchymal transition. Biochim Biophys Acta 1840(8):2621–2634
6. Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15(3):178–196
7. Nieto MA (2013) Epithelial plasticity: a common theme in embryonic and cancer cells. Science 342(6159):1234850
8. Li Y, Ma J, Qian X, Wu Q, Xia J, Miele L, Sarkar FH, Wang Z (2013) Regulation of EMT by Notch signaling pathway in tumor progression. Curr Cancer Drug Targets 13(9):957–962
9. Balogh P, Katz S, Kiss AL (2013) The role of endocytic pathways in TGF-β signaling. Pathol Oncol Res 19(2):141–148
10. Fuxe J, Karlsson MC (2012) TGF-β-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol 22(5–6):455–461
11. Gao D, Vahdat LT, Wong S, Chang JC, Mittal V (2012) Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res 72(19):4883–4889
12. Dave B, Mittal V, Tan NM, Chang JC (2012) Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res 14(1):202
13. Roy I, Evans DB, Dwinell MB (2014) Chemokines and chemokine receptors: Update on utility and challenges for the clinician. Surgery 155(6):961–973
14. Yoshie O (2013) Chemokine receptors as therapeutic targets. Nihon Rinsho Meneki Gakkai Kaishi 36(4):189–196
15. Li W, Chen YQ, Shen YB, Shu HM, Wang XJ, Zhao CL, Chen CJ (2013) HIF-1α knockdown by miRNA decreases survivin expression and inhibits A549 cell growth in vitro and in vivo. Int J Mol Med 32(2):271–280
16. Guha M, Altieri DC (2009) Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle 8(17):2708–2710
17. Lladser A, Sanhueza C, Kiessling R, Quest AF (2011) Is survivin the potential Achilles’ heel of cancer? Adv Cancer Res 111:1–37
18. Ravikumar G, Ananthamurthy A (2014) Cyclin D1 expression in ductal carcinoma of the breast and its correlation with other prognostic parameters. J Cancer Res Ther 10(3):671–675
19. Rekhi B, Motghare P (2014) Cyclin D1 and p16INK4 positive endometrial stromal sarcoma: a case report with new insights. Indian J Pathol Microbiol 57(4):606–608
20. Li T, Zhao X, Mo Z, Huang W, Yan H, Ling Z, Ye Y (2014) Formononetin promotes cell cycle arrest via downregulation of Akt/Cyclin D1/CDK4 in human prostate cancer cells. Cell Physiol Biochem 34(4):1351–1358
21. Soppa U, Schumacher J, Florencio Ortiz V, Pasqualon T, Tejedor FJ, Becker W (2014) The Down syndrome-related protein kinase DYRK1A phosphorylates p27(Kip1) and Cyclin D1 and induces cell cycle exit and neuronal differentiation. Cell Cycle 13(13):2084–2100
22. Yang Y, Ma B, Li L, Jin Y, Ben W, Zhang D, Jiang K, Feng S, Huang L, Zheng J (2014) CDK2 and CDK4 play important roles in promoting the proliferation of SKOV3 ovarian carcinoma cells induced by tumor-associated macrophages. Oncol Rep 31(6):2759–2768
23. Kokontis JM, Lin HP, Jiang SS, Lin CY, Fukuchi J, Hiipakka RA, Chung CJ, Chan TM, Liao S, Chang CH, Chuu CP (2014) Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2. PLoS One 9(10):e109170
24. Ahn SH, Jeong EH, Lee TG, Kim SY, Kim HR, Kim CH (2014) Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells. Cell Oncol (Dordr) 37(5):377–386
25. Xu J, Lamouille S, Derynck R (2009) TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19(2):156–172
26. Wendt MK, Allington TM, Schiemann WP (2009) Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Futur Oncol 5(8):1145–1168
27. Miyazono K (2009) Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci 85(8):314–323